Table 2 Autophagic genes involved in invasion (colonization, proliferation, tumor formation, promotion, metastasis) VS our findings.
Gene expression changes | Cellular outcome | Effect(s) | Consequences on tumor fate | References | Our study findings | |
|---|---|---|---|---|---|---|
43 °C | 48 °C | |||||
ATG5 and ATG7- RAS | Increased autophagy | Mitochondria activation | Tumor formation | 2.63 | 2.94 | |
2.17 | NSC | |||||
ATG16L1 | Autophagy deficiency | Oxidative stress | Tumor suppression | 1346.5 | 1164.1 | |
LC3-II degradation | Damaged mitochondria | |||||
Inflammation induction (1β, IL-18) | 2.05 | 4.58 | ||||
Autophagy activation | p27Kip1 coaded by CDKN1B | CDK-dependent kinase inhibitor | Tumor promotion | 423.14 | 134.83 | |
Autophagy deactivation | ATG3/7/p62 targeting | Pfkfb3 normal expression | Tumor re-proliferation | NSC | NSC | |
2.17 | NSC | |||||
STAT1 inhibition | p27 (CDKN1B), p21(CDKN1A) upregulation | Increase in IDO1 and Kyn receptors | Tumor dormancy | 423.1 | 134.8 | |
Rb hypophosphorylation | Increase in colony formation | |||||
Suppress E2F transcription factor activity | Decrease in proliferation | |||||
AMBRA1 | AMBRA1 role in the modulation of C-MYC phosphorylation and stability | Intracellular switch between autophagy and apoptosis | Colony formation | NSC | 2.05 | |
ATG9B mutation | Autophagy suppression | Blocked recruitment of p62-associated ubiquitinated protein for autophagosome–lysosome degradation | Tumorigenesis | 2.44 | 4.07 | |
GABARAPL1 down-regulation | Disruption of the intracellular transport of receptors and the autophagy pathway | Low GABARAPL1 expression was correlated with a high risk of metastasis | Metastasis | 2.04 | NSC | |
ATG10 up-regulation | Acts as an E2-like enzyme that catalyzes the conjugation of ATG12 to ATG5 and increased autophagy | Lymphovascular invasion | Metastasis | 2.27 | 5.05 | |
RAB24 over-expression | Promote the EMT, adhesion and vasculogenic effects | Promotes the malignant phenotype | Tumor growth, metastasis, EMT activation | 2.76 | 2.23 | |
ATG5 frameshift mutations | Features of cancers with microsatellite instability (MSI) | Common in gastric and colorectal carcinomas | Tumor development by autophagy deregulation | 2.63 | 2.94 | |
CTSB | Dormancy hub gene | Strong biomarker for GBM patient’s survival | Tumor progression | 10.98 | 9.68 | |
Metastasis | ||||||
CXCR4 activation | Independent prognostic factor for disease relapse and survival in acute myeloid leukemia (AML) patients | Increases autophagic activity and decreases | Survival | NSC | 3.64 | |
Colony formation | ||||||
Cytarabine-induced apoptosis | Proliferation | |||||
IGF-1 activation | Activated protein kinase B (AKT) | Inhibit autophagy | Induce apoptosis in drug resistant cells | 2.80 | 2.05 | |
INS over-expression | Precursor of insulin | Insulin signaling and the regulation of autophagy are relevant to neurodegenerative disorders | Survival | 7.81 | 15.51 | |
MAPK8 | Integration point of proliferation, differentiation, transcription regulation and development | Indispensable for TNF superfamily 10 (TNFSF)-induced autophagy | Tumor promotion | 2.96 | NSC | |
Survival | ||||||
PIK3CG | Catalytic subunit of class I PI3Ks | Up-regulated under stress conditions | Cell remodeling and tissue failure | 9.42 | 71.92 | |
MAPK14 | Activation of MAPK14 impairs autophagosome–lysosome fusion | Phosphorylates ATG5 at threonine 75 | Survival promoting autophagy | 2.05 | 2.23 | |
Cell proliferation | ||||||
Migration, Resistance to apoptosis | ||||||
RPS6KB1 | In response to mTOR | Autophagy inhibition | Promote protein synthesis | NSC | 2.08 | |
Cell growth | ||||||
Cell proliferation | ||||||
DRAM2 | Is a lysosomal protein | DRAM2 overexpression induced cell migration proteins including RAC1, RHOA, RHOC, ROCK1, and decreased RHOB expression | Metastasis | 2.05 | NSC | |
Proliferation | ||||||
Migration | ||||||
Cell cycle activation | ||||||
LAMP1 | LAMP1 is lysosomal marker | LAMP1 overexpression reversed the antitumor effects of UBL4A in pancreatic cancer | Cell proliferation | 3.64 | 3.08 | |
Migration | ||||||
Invasion | ||||||
mTOR | Key regulator of protein synthesis via 4EBP1 and p70S6K1/2 phosphorylation | Increases the translational capacity of cancer cells | Autophagy inhibition | 6.04 | 6.48 | |
Dormancy | ||||||
Metastasis | ||||||
RPLP0 | Belongs to the L10P family of ribosomal proteins | Affected p21 expression | Cell promotion | NSC | 619.5 | |
Induction | Autophagy induction (Survival) in response to RPLP deficiency stress | |||||
G1 arrest of gastric cancer cells | ||||||
CTSS | Is a lysosomal cysteine protease that may participate in the degradation of antigenic proteins | Cleaves some extracellular matrix (ECM) proteins | Tumorigenesis stimulation | 11.35 | NSC | |
Metastasis | ||||||
ESR1 | Point mutations on ESR1 are drivers for resistance, and promote of ERα without the bound ligand | Ligand independently ER stimulation | Proliferation | 9.68 | 4.16 | |
Long-distance metastasis | ||||||
Autophagy manipulation | eIF4E/eIF4GI knockdown | The decrease in ERα, SMAD5, NFkB, CyclinD1, c-MYC, and HIF1α | The decrease in EMT promoter | 1049.1 | 1904 | |
Increase in EMT inhibitors | ||||||
The decrease in migration capability | ||||||